Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

of the Symphony Allegro Development Board. "These promising initial results are exciting. We look forward to working with our colleagues at Symphony Allegro to further analyze the data and determine the next steps in the clinical development of AZ-104."

AZ-104 Phase 2a Clinical Trial Design

The Phase 2a clinical trial was an in-clinic, multi-center, randomized, double blind, placebo-controlled study. The study was designed to evaluate the treatment of a single migraine attack in each of 160 migraine patients, with or without aura. In the trial design, three doses of AZ-104 (Staccato loxapine in 1.25, 2.5 and 5 mg doses) were evaluated against placebo (a Staccato device containing no drug). Patients reported to the clinic when they felt the onset of a migraine and were treated once their headache was considered to be of moderate or severe intensity. Patients stayed in the clinic for 4 hours post-dosing for various assessments and were monitored via patient diary for the remainder of the 24-hour evaluation period. The clinical trial enrolled 168 patients: 43 patients in the 1.25 mg dose group, 43 patients in the 2.5 mg dose group, 43 patients in the 5 mg dose group and 39 patients in the placebo dose group.

Patients rated their headache pain using the International Headache Society (IHS) 4-point rating scale. The primary efficacy endpoint was headache pain relief (headache pain rated as mild or none) at 2-hours post-dose. Secondary efficacy endpoints for the trial included various additional measurements of pain relief, as well as effects on nausea, vomiting, phonophobia and photophobia. All results were considered statistically significant at the p < 0.05 level and all analyses were made on an intent-to-treat basis. Side effects were recorded throughout the clinical trial study period.

Primary Efficacy Endpoint

AZ-104 met the primary efficacy endpoint of the clinical trial for two doses of the drug compared to placebo. Statistically
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop ... New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists will ... that hyperspectral imaging can bring to examination procedures. ... Director of Product Development at ChemImage, will host ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... AMSTERDAM, May 31, 2011 Leading events organiser ... UBM), announced details of a new Logistics and Supply ... event dedicated to pharmaceutical contract services and outsourcing. ICSE ... Messe Frankfurt, Germany and is part of the world,s ...
... 2011 Volcano Corporation (NASDAQ: VOLC ), a ... guidance tools designed to enhance the treatment of coronary and ... in the Goldman Sachs 32nd Annual Global Healthcare Conference on ... 2:40 p.m., Pacific Daylight Time (5:40 p.m., Eastern Daylight Time). ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3
(Date:9/1/2014)... Mass., (PRWEB) September 01, 2014 BCC ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , ... $21.8 million in 2013 and is expected to reach ... grow to $471.5 million by 2019, which is equivalent ... through 2019. The receptor-mediated transport (RMT) segment is forecasted ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Beginning Tuesday, ... over 3,000 medical professionals and 10,000 consumers for the ... a 5-day gathering of the nation’s top medical professionals ... diseases or conditions. The week-long event contains more than ... scientific instruction available in the pain management field. , ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
... Yoplait Presents Concert Featuring Music Icon and Breast Cancer Survivor ... ... marks the milestone 10th,anniversary of Save Lids to Save Lives(R), Yoplait(R),s signature ... raise awareness,and funds for breast cancer. To date, Yoplait has donated more ...
... Merchant Gift ... Card, ... innovative prepaid debit programs, and Sodexo, a leading,foodservice and facilities management company ... the Esteem Pass(TM).,Esteem Pass is a filtered merchant prepaid debit card program ...
... Sept. 9 Autovan, LLC, a specialty,vehicle manufacturer ... use markets today announced a donation to Easter ... an Easter Seals, Foxworth,home in Rochester, New York., ... strong community advocate,for people with disabilities, joined Easter ...
... John Carrier announced today the addition of ... tools featuring a new line of ... sets __title__ KT Pro Tools]. These integrated ... first and Reid Supply has them ready ...
... territory by making their affordable health insurance products ... Quotebroker specializes in providing free health insurance quotes ... have difficulty obtaining affordable health insurance. They provide ... and associations across the state of Arizona for ...
... company, is thrilled to be included in Inc.,s 27th ... in the country. As the fastest growing company in ... to other healthcare staffing firms making the list it ... traveling healthcare staffing companies. It is the only company ...
Cached Medicine News:Health News:Yoplait(R) Celebrates 10th Anniversary of Save Lids to Save Lives(R) and Sustained Commitment to Fight Against Breast Cancer 2Health News:Yoplait(R) Celebrates 10th Anniversary of Save Lids to Save Lives(R) and Sustained Commitment to Fight Against Breast Cancer 3Health News:Yoplait(R) Celebrates 10th Anniversary of Save Lids to Save Lives(R) and Sustained Commitment to Fight Against Breast Cancer 4Health News:Sodexo Releases Innovative Prepaid Incentive Card Powered by eCommLink 2Health News:Sodexo Releases Innovative Prepaid Incentive Card Powered by eCommLink 3Health News:Autovan Donates Wheelchair-Accessible Van; Brings Greater Mobility to Facility in Rochester, New York 2Health News:Reid Supply Introduces Lifetime Warranty on New Line of Hand Tools 2Health News:Reid Supply Introduces Lifetime Warranty on New Line of Hand Tools 3Health News:Reid Supply Introduces Lifetime Warranty on New Line of Hand Tools 4Health News:Quotebroker Expands Territory by Offering Affordable Health Insurance Quotes to Arizona Residents 2Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 2Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 3Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 4
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... AliMed® Turnbuckle Ankle Orthosis enables ... torque at the ankle joint to ... The splint features a pair of ... and eversion/inversion simultaneously. Simply adjust the ...
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... As a prophylaxis for deep vein thrombosis, ... combination of graduated sequential compression and rapid ... formation by increasing venous ejection while producing ... System includes a pump with tube assembly ...
Medicine Products: